FCX vs MLTX · P/E 38, rev $13.26B vs $1.41B cap
Freeport-McMoran Copper & Gold Inc (FCX) versus MoonLake Immunotherapeutics (MLTX) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
MoonLake Immunotherapeutics (MLTX) is a biotechnology company listed on US.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
MLTX does not have a complete income-statement cache yet.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. MLTX currently screens at market cap $1.41B.
Not investment advice. Open the FCX and MLTX stock pages for the full models.
Not investment advice.